The India-made vaccine Covaxin, developed by Hyderabad-based Bharat Biotech, can neutralize the B1617 variant of the coronavirus, White House chief medical adviser Dr Anthony Fauci has said.
“Now this is something we are still getting data on, but the most recent data regarding convalescent sera from Covid-19 cases in people who have received Covaxin, it has been found to neutralize variant 617 “said Fauci during the White House press point.
Fauci, who is the chief advisor to US President Joe Biden on the Covid pandemic, cited recent Phase 3 clinical trials of Covaxin by the ICMR, which claimed the vaccine neutralizes several variants of SARS-CoV-2 and effectively neutralizes the double mutant strain (B1617) as well. He called “vaccination an important antidote”.
“An ICMR study shows that Covaxin neutralizes against several variants of SARS-CoV-2 and also effectively neutralizes the double mutant strain,” ICMR said in a tweet. The ICMR study also demonstrated the neutralizing potential of Covaxin against the British variant and the Brazilian variant.
He also successfully isolated and cultivated the double mutant strain B1617 SARS-CoV-2 identified in parts of India and several other countries. “Covaxin has also been shown to effectively neutralize the double mutant strain,” said ICMR.
Developed by Bharat Biotech in partnership with the National Institute of Virology and the Indian Council for Medical Research, Covaxin was approved for emergency use on January 3. The results of the trials later showed that the vaccine was 78 percent effective.
The second wave of coronavirus, which crippled India’s healthcare system with a lack of oxygen and others, highlighted global inequalities, Fauci said, adding that countries had failed to unite to provide an adequate global response to prevent the “tragic” coronavirus outbreak from overwhelming India. .
“The only way to adequately respond to a global pandemic is to have a global response, and a global response means fairness around the world,” the Guardian said, quoting Fauci.
“And this is something that unfortunately has not been accomplished. Often times when you have diseases in which there is a limited amount of intervention, whether therapeutic or preventive, it is something that all countries that are relatively wealthy or higher income countries need to pay more attention, ”he added.
In response to a question, Dr Andy Slavitt, the White House’s senior COVID-19 response adviser, said a Center for Disease Control and Prevention strike team is traveling to India to help coordinate this response.
“We are making sure to locate some of the raw materials needed to create more vaccines in India, which I think will be a big help there,” he said.
“We are supporting the Indian country during this tragic and trying surge. We are working to deploy resources and supplies including therapeutics, rapid test kits, ventilators, PPE and raw materials needed to manufacture vaccines in India CDC, which has long worked with and in India on public health measures, will deploy a strike team around the country to support public health efforts in that country, ”Slavitt said.
Meanwhile, India recorded 360,960 new cases in the 24 hours leading up to Wednesday morning, according to data from the Ministry of Health, another new daily world record. The ministry also said the total death toll in India had passed 200,000 to 201,187.